Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.75 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | EHD1 | Q9H4M9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003321 | 1.00 | EPHA2 (0.75) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL22730944 | 0.86 | EPHA2 (0.65) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL22328117 | 0.86 | EPHA2 (1.00) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL19003330 | 0.84 | PTGER2 (0.69) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL23598456 | 0.83 | PTGER2 (0.69) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL19003389 | 0.83 | EGFR (0.65) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL23598453 | 0.83 | EGFR (0.65) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL24548693 | 0.83 | EGFR (0.65) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL23598434 | 0.83 | PTGER2 (0.63) | EPHA2PTGER2EGFRNFKBIAAKT1 | |
| SCHEMBL19003388 | 0.83 | PTGER2 (0.63) | EPHA2PTGER2EGFRNFKBIAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195524-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MANAGEMENT OF NEURODEGERATIVE DISEASES | UNIV SOUTH FLORIDA (US) | 2022-06-23 | — | — | US | disclosed |
| US-11214835-B1 | Methods and compositions for diagnosis and management of neurodegerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210198221-A1 | GAS5 BINDING COMPOUNDS, FORMULATIONS, AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA (US) | 2021-07-01 | — | — | US | disclosed |
| WO-2017106505-A1 | GAS5 BINDING COMPOUNDS, FORMULATIONS, AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214835-B1 | Methods and compositions for diagnosis and management of neurodegerative diseases | PSEN2, CLN6, PSEN1 | EPHA2 2750/4885PTGER2 3674/4885EGFR 3609/4885 |
| US-20210198221-A1 | GAS5 BINDING COMPOUNDS, FORMULATIONS, AND USES THEREOF | METTL16, ALKBH5, RBM25 | EPHA2 2855/4885PTGER2 4087/4885EGFR 1811/4885 |
| US-20220195524-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MANAGEMENT OF NEURODEGERATIVE DISEASES | PSEN2, CLN6, PSEN1 | EPHA2 2750/4885PTGER2 3674/4885EGFR 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.